HK1143551A1 - Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin - Google Patents
Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatinInfo
- Publication number
- HK1143551A1 HK1143551A1 HK10110187.0A HK10110187A HK1143551A1 HK 1143551 A1 HK1143551 A1 HK 1143551A1 HK 10110187 A HK10110187 A HK 10110187A HK 1143551 A1 HK1143551 A1 HK 1143551A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- complexes
- carboplatin
- phosphaplatins
- platinum
- fas
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 229960004562 carboplatin Drugs 0.000 title abstract 3
- 190000008236 carboplatin Chemical compound 0.000 title abstract 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
- 229910052697 platinum Inorganic materials 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000861 pro-apoptotic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95412607P | 2007-08-06 | 2007-08-06 | |
| US97392607P | 2007-09-20 | 2007-09-20 | |
| PCT/US2008/072398 WO2009021082A2 (en) | 2007-08-06 | 2008-08-06 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1143551A1 true HK1143551A1 (en) | 2011-01-07 |
Family
ID=40342030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10110187.0A HK1143551A1 (en) | 2007-08-06 | 2010-10-29 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7700649B2 (zh) |
| EP (2) | EP2668949A1 (zh) |
| JP (2) | JP5385274B2 (zh) |
| CN (1) | CN101801369B (zh) |
| CY (1) | CY1115504T1 (zh) |
| DK (1) | DK2173337T3 (zh) |
| ES (1) | ES2495743T3 (zh) |
| HK (1) | HK1143551A1 (zh) |
| HR (1) | HRP20140808T1 (zh) |
| PL (1) | PL2173337T3 (zh) |
| PT (1) | PT2173337E (zh) |
| SI (1) | SI2173337T1 (zh) |
| WO (2) | WO2009021082A2 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2668949A1 (en) | 2007-08-06 | 2013-12-04 | Ohio University | Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
| CN103037859A (zh) * | 2010-06-04 | 2013-04-10 | 俄亥俄大学 | 磷铂及其在治疗癌症中的用途 |
| EP2663301A1 (en) * | 2011-01-12 | 2013-11-20 | Ohio University | Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof |
| KR101901477B1 (ko) | 2011-07-08 | 2018-09-21 | 다우 글로벌 테크놀로지스 엘엘씨 | 블로운 필름에 적합한 폴리에틸렌 배합 조성물, 그 제조 방법, 및 그로부터 제조된 필름 |
| MX357865B (es) | 2011-10-05 | 2018-07-25 | N Bose Rathindra | Procedimientos eficientes para preparación a gran escala de agentes antitumorales de fosfaplatinos. |
| CN104010508B (zh) * | 2011-10-05 | 2017-03-15 | 理辛德拉·N·博斯 | 用于大规模制备磷铂类抗肿瘤剂的高效方法 |
| CN110269940A (zh) | 2011-10-20 | 2019-09-24 | 奈瑞姆生物技术公司 | 用于治疗癌症的治疗组合 |
| HUE046327T2 (hu) * | 2012-05-24 | 2020-03-30 | Phosplatin Therapeutics Llc | Tisztítási eljárás foszfaplatin vegyületekhez |
| JP6382231B2 (ja) * | 2013-02-22 | 2018-08-29 | ユニバーシティ オブ ヒューストンＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈｏｕｓｔｏｎ | 神経保護剤としてのホスファプラチン |
| EP3107534A4 (en) * | 2014-02-19 | 2017-09-06 | The University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
| JP7304128B2 (ja) | 2014-06-11 | 2023-07-06 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 白金耐性の克服における使用のためのテキサフィリン－白金（ｉｖ）コンジュゲート及び組成物 |
| EP3397642A1 (en) | 2015-12-30 | 2018-11-07 | Atilim Universitesi | Dna targeted mono and heterodinuclear complexes |
| CN110381952B (zh) * | 2017-01-06 | 2023-10-20 | 弗斯普拉廷治疗有限公司 | 作为治疗剂用于治疗骨癌或血癌的磷铂化合物 |
| CA3074020A1 (en) * | 2017-09-08 | 2019-03-14 | Phosplatin Therapeutics Llc | Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4234500A (en) | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes |
| US4291027A (en) | 1979-03-07 | 1981-09-22 | Engelhard Minerals & Chemicals Corp. | Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes |
| CA2017739A1 (en) * | 1989-07-18 | 1991-01-18 | Leslie S. Hollis | Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents |
| JP4463274B2 (ja) * | 2003-06-27 | 2010-05-19 | 明 小谷 | ビスホスホネート錯体 |
| EP2177525A1 (en) * | 2007-07-06 | 2010-04-21 | TMRC Co., Ltd. | Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound |
| EP2668949A1 (en) | 2007-08-06 | 2013-12-04 | Ohio University | Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
-
2008
- 2008-08-06 EP EP13182512.7A patent/EP2668949A1/en not_active Withdrawn
- 2008-08-06 PL PL08797320T patent/PL2173337T3/pl unknown
- 2008-08-06 WO PCT/US2008/072398 patent/WO2009021082A2/en active Application Filing
- 2008-08-06 DK DK08797320.2T patent/DK2173337T3/da active
- 2008-08-06 WO PCT/US2008/072397 patent/WO2009021081A2/en not_active Application Discontinuation
- 2008-08-06 ES ES08797320.2T patent/ES2495743T3/es active Active
- 2008-08-06 SI SI200831280T patent/SI2173337T1/sl unknown
- 2008-08-06 US US12/187,376 patent/US7700649B2/en active Active
- 2008-08-06 JP JP2010520294A patent/JP5385274B2/ja active Active
- 2008-08-06 CN CN2008801015774A patent/CN101801369B/zh active Active
- 2008-08-06 PT PT87973202T patent/PT2173337E/pt unknown
- 2008-08-06 EP EP08797320.2A patent/EP2173337B1/en active Active
-
2010
- 2010-03-11 US US12/722,189 patent/US8034964B2/en active Active
- 2010-10-29 HK HK10110187.0A patent/HK1143551A1/xx unknown
-
2011
- 2011-08-30 US US13/221,458 patent/US8445710B2/en active Active
-
2013
- 2013-03-15 US US13/842,885 patent/US8653132B2/en active Active
- 2013-06-07 JP JP2013120309A patent/JP5647300B2/ja active Active
-
2014
- 2014-08-27 HR HRP20140808AT patent/HRP20140808T1/hr unknown
- 2014-08-27 CY CY20141100686T patent/CY1115504T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20140808T1 (hr) | 2014-10-24 |
| EP2668949A1 (en) | 2013-12-04 |
| JP5647300B2 (ja) | 2014-12-24 |
| US8034964B2 (en) | 2011-10-11 |
| US8445710B2 (en) | 2013-05-21 |
| SI2173337T1 (sl) | 2014-10-30 |
| PL2173337T3 (pl) | 2014-11-28 |
| DK2173337T3 (da) | 2014-09-15 |
| EP2173337A4 (en) | 2010-10-27 |
| US20100233293A1 (en) | 2010-09-16 |
| CN101801369A (zh) | 2010-08-11 |
| WO2009021081A3 (en) | 2009-05-07 |
| EP2173337B1 (en) | 2014-07-30 |
| CN101801369B (zh) | 2012-09-19 |
| WO2009021082A2 (en) | 2009-02-12 |
| US8653132B2 (en) | 2014-02-18 |
| US20090042838A1 (en) | 2009-02-12 |
| ES2495743T3 (es) | 2014-09-17 |
| WO2009021082A3 (en) | 2009-04-23 |
| JP5385274B2 (ja) | 2014-01-08 |
| EP2173337A2 (en) | 2010-04-14 |
| US20130237503A1 (en) | 2013-09-12 |
| US20110313182A1 (en) | 2011-12-22 |
| PT2173337E (pt) | 2014-09-03 |
| JP2010535803A (ja) | 2010-11-25 |
| JP2013227218A (ja) | 2013-11-07 |
| US7700649B2 (en) | 2010-04-20 |
| CY1115504T1 (el) | 2017-01-04 |
| WO2009021081A2 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1143551A1 (en) | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin | |
| Vojtek et al. | Anticancer activity of palladium-based complexes against triple-negative breast cancer | |
| Wang et al. | Emerging platinum (IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment | |
| Zhou et al. | Photothermally triggered copper payload release for cuproptosis‐promoted cancer synergistic therapy | |
| Mehmood | Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments | |
| Farrell | Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets | |
| Reedijk | Platinum anticancer coordination compounds: study of DNA binding inspires new drug design | |
| Kawata et al. | In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells | |
| Xiao et al. | A dual-targeting hybrid platinum (IV) prodrug for enhancing efficacy | |
| NZ628423A (en) | Methods of treating cancer | |
| Karnthaler‐Benbakka et al. | Tumor‐targeting of EGFR inhibitors by hypoxia‐mediated activation | |
| Horvath et al. | Supramolecular nanoencapsulation as a tool: Solubilization of the anticancer drug trans-dichloro (dipyridine) platinum (II) by complexation with β-cyclodextrin | |
| MA32394B1 (fr) | Composes pegyles d'insuline lispro | |
| BR112015015319A2 (pt) | composições de nanopartícula de albumina e paclitaxel | |
| EP2796554A3 (en) | Compositions for use in treating BCL2-associated cancers | |
| IL184872A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
| WO2010132879A3 (en) | Multicomponent degradable cationic polymers | |
| Chin et al. | Synthesis, characterization and biological properties of cobalt (II) complexes of 1, 10-phenanthroline and maltol | |
| MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
| Ramos-Lima et al. | Structural characterization, DNA interactions, and cytotoxicity of new transplatin analogues containing one aliphatic and one planar heterocyclic amine ligand | |
| Xiao et al. | Cleavage enhancement of specific chemical bonds in DNA by cisplatin radiosensitization | |
| MX2021008261A (es) | Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso. | |
| Leung et al. | Epigenetic modulation by inorganic metal complexes | |
| Yu et al. | Orthogonal γPNA dimerization domains empower DNA binders with cooperativity and versatility mimicking that of transcription factor pairs | |
| Parveen et al. | RNA-targeted Cu (II)-based potential antitumor drug entity: Comprehensive structural, biological {DNA/RNA binding, cleavage, cytotoxicity} and computational studies |